UnitedHealth Group Incorporated $UNH Shares Sold by Second Line Capital LLC

Key Points

• Second Line Capital LLC dramatically cut its stake in UnitedHealth, selling 5,275 shares in Q3 and reducing holdings by 84.1% to 994 shares valued at about $343,000.
• Wall Street views are mixed but tilted positive: the consensus rating is a Moderate Buy with an average target of $372.13, even as some firms (JPMorgan, Leerink) trimmed price targets and Weiss Ratings lowered its rating to a sell.
• UnitedHealth beat Q1 expectations with $2.11 EPS and $113.73 billion in revenue (up 12.3% YoY), recently paid a $2.21 quarterly dividend (≈3.1% yield), and provided FY‑2026 EPS guidance that investors will watch versus analyst forecasts.

Second Line Capital LLC lessened its holdings in shares of UnitedHealth Group Incorporated (NYSE:UNH - Free Report) by 84.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 994 shares of the healthcare conglomerate's stock after selling 5,275 shares during the period. Second Line Capital LLC's holdings in UnitedHealth Group were worth $343,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. North Capital Inc. grew its stake in shares of UnitedHealth Group by 16.2% in the third quarter. North Capital Inc. now owns 194 shares of the healthcare conglomerate's stock worth $67,000 after purchasing an additional 27 shares in the last quarter. Sunflower Bank N.A. raised its stake in shares of UnitedHealth Group by 1.5% during the third quarter. Sunflower Bank N.A. now owns 1,916 shares of the healthcare conglomerate's stock valued at $662,000 after purchasing an additional 28 shares in the last quarter. Axis Wealth Partners LLC grew its position in UnitedHealth Group by 1.7% in the 3rd quarter. Axis Wealth Partners LLC now owns 1,631 shares of the healthcare conglomerate's stock valued at $563,000 after buying an additional 28 shares in the last quarter. Abound Wealth Management raised its position in shares of UnitedHealth Group by 13.5% during the 3rd quarter. Abound Wealth Management now owns 244 shares of the healthcare conglomerate's stock worth $84,000 after buying an additional 29 shares in the last quarter. Finally, Auxano Advisors LLC lifted its stake in shares of UnitedHealth Group by 3.4% in the 3rd quarter. Auxano Advisors LLC now owns 964 shares of the healthcare conglomerate's stock worth $333,000 after acquiring an additional 32 shares during the period. 87.86% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. dropped their target price on UnitedHealth Group from $425.00 to $389.00 and set an "overweight" rating on the stock in a report on Monday, February 2nd. Sanford C. Bernstein reissued an "outperform" rating on shares of UnitedHealth Group in a research note on Wednesday, January 28th. Evercore raised UnitedHealth Group to a "strong-buy" rating in a research note on Tuesday, January 6th. Weiss Ratings cut shares of UnitedHealth Group from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Monday, March 2nd. Finally, Leerink Partners reduced their price objective on shares of UnitedHealth Group from $410.00 to $345.00 and set an "outperform" rating for the company in a research report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $372.13.

More UnitedHealth Group News

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: Analyst bullish thesis highlighting AI-driven efficiency and a targeted $1B in cost savings, plus management’s 2026 EPS guidance, supports expectations for margin improvement and earnings recovery. UnitedHealth: Why AI Is The Secret Weapon For The Turnaround
• Positive Sentiment: UnitedHealthcare expanded national doula coverage for employer plans — a value-based, preventive care move that could improve maternal outcomes and reduce downstream costs if utilization and ROI track expectations. UNH Expands Doulas: Better Outcomes or Margin Play Ahead?
• Neutral Sentiment: The company set its Q1 2026 earnings release for April 21 (pre-market) with a webcast — an upcoming report that could drive volatility depending on revenue/margin progress vs. the current EPS guidance. UnitedHealth Group Announces Earnings Release Date
• Neutral Sentiment: Coverage and commentary summarizing a bullish investment case (valuation-focused writeups) keep the narrative mixed—some investors see a longer-term buy opportunity while others wait for clearer execution. Is UnitedHealth Group Incorporated (UNH) A Good Stock To Buy Now?
• Negative Sentiment: Critical research argues the stock is stabilizing but not yet a buy—analysts caution that membership and revenue adjustments reflect strategic resets, and valuation compression leaves limited margin of safety until execution is proven. UnitedHealth: Stabilizing, But Not Yet A Buy

UnitedHealth Group Stock Up 0.7%

Shares of UnitedHealth Group stock opened at $287.60 on Wednesday. The company has a quick ratio of 0.79, a current ratio of 0.79 and a debt-to-equity ratio of 0.72. UnitedHealth Group Incorporated has a 12-month low of $234.60 and a 12-month high of $606.36. The firm has a market capitalization of $261.05 billion, a PE ratio of 21.80, a price-to-earnings-growth ratio of 1.31 and a beta of 0.41. The stock's fifty day moving average is $301.00 and its 200-day moving average is $324.98.

UnitedHealth Group (NYSE:UNH - Get Free Report) last issued its quarterly earnings results on Tuesday, January 27th. The healthcare conglomerate reported $2.11 earnings per share for the quarter, topping analysts' consensus estimates of $2.09 by $0.02. UnitedHealth Group had a return on equity of 14.79% and a net margin of 2.69%.The firm had revenue of $113.73 billion for the quarter, compared to analysts' expectations of $113.38 billion. During the same quarter last year, the business posted $6.81 EPS. UnitedHealth Group's revenue was up 12.3% on a year-over-year basis. UnitedHealth Group has set its FY 2026 guidance at 17.750- EPS. Equities analysts anticipate that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current year.

UnitedHealth Group Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 17th. Investors of record on Monday, March 9th were paid a $2.21 dividend. The ex-dividend date of this dividend was Monday, March 9th. This represents a $8.84 dividend on an annualized basis and a yield of 3.1%. UnitedHealth Group's dividend payout ratio (DPR) is currently 67.02%.

About UnitedHealth Group

UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

UnitedHealthcare is the company's benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.

Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.